retatrutide mechanism triple agonist glp-1 gip glucagon The Road towards Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Receptor - An Update Cagrilintide vs Retatrutide Compared |

Professor Kuhnle told MailOnline: 'The studies are all very small

The dose-response relationship observed in trials provides useful clinical guidance

Serious but Less Common Side Effects: Pancreatitis: There is a risk of pancreatitis (inflammation of the pancreas), which is typically associated with a history of pancreatic disorders

Key resources include: ClinicalTrials.gov Search for new trials involving cagrilintide or retatrutide PubMed/MEDLINE Set alerts for publications on these compounds Major medical journals New England Journal of Medicine, The Lancet, JAMA for high-impact studies Endocrine Society conferences Annual meetings where phase 3 data is often first presented FDA briefing documents Detailed safety and efficacy data released during approval processes Understanding the broader landscape of peptide research helps contextualize developments with specific compounds